Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $143.80 -1.55%
EPS Growth %: -7.5%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
NLY, CP, RUSHA, More
EPS Growth %: -7.5%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ford (F) earnings beat estimates in Q1, revenue falls short; stock up
- Oceaneering (OII) Tops Q1 EPS by 5c, confirms prior guidance
- First Bancorp. (FBNC) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
